US Bancorp
LOGC

US Bancorp’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

US Bancorp’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,000
Closed -$1K – 4340
2022
Q3 		$1K Hold
2,000
– – ﹤0.01% 4048
2022
Q2 		$1K Hold
2,000
– – ﹤0.01% 4049
2022
Q1 		$1K Hold
2,000
– – ﹤0.01% 4044
2021
Q4 		$5K Hold
2,000
– – ﹤0.01% 3687
2021
Q3 		$9K Hold
2,000
– – ﹤0.01% 3505
2021
Q2 		$9K Hold
2,000
– – ﹤0.01% 3464
2021
Q1 		$15K Hold
2,000
– – ﹤0.01% 3158
2020
Q4 		$15K Hold
2,000
– – ﹤0.01% 3037
2020
Q3 		$18K Buy
2,000
+1,250
+167% +$9.48K ﹤0.01% 2865
2020
Q2 		$6K Hold
750
– – ﹤0.01% 3281
2020
Q1 		$4K Hold
750
– – ﹤0.01% 3343
2019
Q4 		$5K Buy
+750
New +$6.78K ﹤0.01% 3298

US Bancorp's LOGC Position: Q4 2022 in Review

US Bancorp sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 2,000 shares — an estimated $1K sold.

US Bancorp first reported a position in LOGC in Q4 2019 and held it in 12 quarters. The position peaked at $18K in Q3 2020. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

  • US Bancorp reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • US Bancorp sold 2,000 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1K.
  • US Bancorp first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2019 and held it in 12 quarters.
  • US Bancorp's LogicBio Therapeutics, Inc. Common Stock position peaked at $18K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on US Bancorp's 13F filing for Q4 2022, filed 13 Feb 2023.